This website uses cookies. Some are necessary to help our website work properly and can't be switched off, and some are optional but can optimise your browsing experience. To manage your cookie choices, click on Open settings.
Russia: AstraZeneca and Gamaleya trials of COVID vaccine combinations to start - Dmitriev03:33

Russia: AstraZeneca and Gamaleya trials of COVID vaccine combinations to start - Dmitriev

Russian Federation
December 21, 2020 at 20:41 GMT +00:00 · Published

Clinical trials of COVID-19 vaccine combinations between Gamaleya Institute and the British-Swedish company AstraZeneca will be launched in three countries, CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev announced during an interview with RT on Monday.

AstraZeneca announced two weeks ago that it would team up with scientists from Gamaleya Institute to determine whether their own experimental formula could produce better results if it incorporated elements of the Russian jab.

According to Dmitriev, the British-Swedish company appreciated the approach of the Sputnik V vaccine, which used two different shot vectors to support the immune system, while other vaccines use the same vectors twice, which is less effective according to Dmitriev. He also said the 'Lite' vaccine can offer "quite a high level of protection" of "between 70 percent and 85 percent" from a single shot. Most coronavirus vaccines require at least two rounds of jabs to be effective, which may be costly for poorer countries.

He also praised the cooperation between British-Swedish company AstraZeneca and Gamaleya Research Institute, noting that cooperation is needed to work on the shortage of vaccines that countries will face, even if the planned amount of vaccines were produced.

Dmitriev declared that around 500 million doses of Sputnik V will be produced during next year, adding that one billion doses could be produced in many other countries as well.

"We expect some trials to start as early as this year. We expect three countries to participate in clinical trials. Some in the CIS countries, some in the Middle East and basically we expect them to last several months,” he said.

The CEO announced that a one-shot "Sputnik V Lite” vaccine is to be produced at the beginning of 2021, the light version is the first shot of the Sputnik V vaccine.

“Even our first shot is causing quite a high level of protection so basically based on the age groups its protection between 70 percent and 85 percent which is still higher than for many other vaccines,” the CEO explained.

Dmitriev reassured again that the Sputnik V vaccine is effective against the new coronavirus strain found in Europe, adding that, the “Sputnik vaccine is effective to deal with this mutation and we actually had a number of spike mutations before and it did not affect the Sputnik V efficacy in any way, it still shows more than 90 percent efficacy and 100 percent efficacy to prevent of strong cases.”

Russia: AstraZeneca and Gamaleya trials of COVID vaccine combinations to start - Dmitriev03:33
Top downloads in last 24 hours
Show more
Description

Clinical trials of COVID-19 vaccine combinations between Gamaleya Institute and the British-Swedish company AstraZeneca will be launched in three countries, CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev announced during an interview with RT on Monday.

AstraZeneca announced two weeks ago that it would team up with scientists from Gamaleya Institute to determine whether their own experimental formula could produce better results if it incorporated elements of the Russian jab.

According to Dmitriev, the British-Swedish company appreciated the approach of the Sputnik V vaccine, which used two different shot vectors to support the immune system, while other vaccines use the same vectors twice, which is less effective according to Dmitriev. He also said the 'Lite' vaccine can offer "quite a high level of protection" of "between 70 percent and 85 percent" from a single shot. Most coronavirus vaccines require at least two rounds of jabs to be effective, which may be costly for poorer countries.

He also praised the cooperation between British-Swedish company AstraZeneca and Gamaleya Research Institute, noting that cooperation is needed to work on the shortage of vaccines that countries will face, even if the planned amount of vaccines were produced.

Dmitriev declared that around 500 million doses of Sputnik V will be produced during next year, adding that one billion doses could be produced in many other countries as well.

"We expect some trials to start as early as this year. We expect three countries to participate in clinical trials. Some in the CIS countries, some in the Middle East and basically we expect them to last several months,” he said.

The CEO announced that a one-shot "Sputnik V Lite” vaccine is to be produced at the beginning of 2021, the light version is the first shot of the Sputnik V vaccine.

“Even our first shot is causing quite a high level of protection so basically based on the age groups its protection between 70 percent and 85 percent which is still higher than for many other vaccines,” the CEO explained.

Dmitriev reassured again that the Sputnik V vaccine is effective against the new coronavirus strain found in Europe, adding that, the “Sputnik vaccine is effective to deal with this mutation and we actually had a number of spike mutations before and it did not affect the Sputnik V efficacy in any way, it still shows more than 90 percent efficacy and 100 percent efficacy to prevent of strong cases.”